Y
Yuan Hou
Researcher at Cleveland Clinic Lerner Research Institute
Publications - 48
Citations - 2616
Yuan Hou is an academic researcher from Cleveland Clinic Lerner Research Institute. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 27 publications receiving 1493 citations. Previous affiliations of Yuan Hou include Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Yadi Zhou,Yuan Hou,Jiayu Shen,Yin Huang,William R. Martin,Feixiong Cheng,Feixiong Cheng,Feixiong Cheng +7 more
TL;DR: This study presents an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network.
Journal ArticleDOI
New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.
Yuan Hou,Junfei Zhao,William R. Martin,Asha R. Kallianpur,Asha R. Kallianpur,Mina K. Chung,Mina K. Chung,Mina K. Chung,Lara Jehi,Nima Sharifi,Nima Sharifi,Serpil C. Erzurum,Serpil C. Erzurum,Charis Eng,Feixiong Cheng,Feixiong Cheng,Feixiong Cheng +16 more
TL;DR: This study suggested that ACE2 or TMPRSS2 DNA polymorphisms were likely associated with genetic susceptibility of COVID-19, which calls for a human genetics initiative for fighting the COVID -19 pandemic.
Journal ArticleDOI
Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning.
Xiangxiang Zeng,Xiang Song,Tengfei Ma,Xiaoqin Pan,Yadi Zhou,Yuan Hou,Zheng Zhang,Kenli Li,George Karypis,Feixiong Cheng,Feixiong Cheng,Feixiong Cheng +11 more
TL;DR: There have been more than 2.2 million confirmed cases and over 120,000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coro...
Journal ArticleDOI
A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19
Yadi Zhou,Yuan Hou,Jiayu Shen,Reena Mehra,Reena Mehra,Asha R. Kallianpur,Asha R. Kallianpur,Daniel A. Culver,Daniel A. Culver,Michaela U. Gack,Samar Farha,Samar Farha,Joe Zein,Joe Zein,Suzy A.A. Comhair,Suzy A.A. Comhair,Claudio Fiocchi,Claudio Fiocchi,Thaddeus Stappenbeck,Thaddeus Stappenbeck,Timothy A. Chan,Timothy A. Chan,Charis Eng,Jae U. Jung,Jae U. Jung,Lara Jehi,Lara Jehi,Serpil C. Erzurum,Serpil C. Erzurum,Feixiong Cheng,Feixiong Cheng,Feixiong Cheng +31 more
TL;DR: This study identified melatonin usage was associated with a reduced likelihood of SARS-CoV-2 positive test result compared to use of angiotensin II receptor blockers, and presented an integrative network medicine platform for predicting disease manifestations associated with CO VID-19 and identifying melatonin for potential prevention and treatment of COVID-19.
Journal ArticleDOI
A genome-wide positioning systems network algorithm for in silico drug repurposing.
Feixiong Cheng,Weiqiang Lu,Chuang Liu,Jiansong Fang,Yuan Hou,Diane E. Handy,Rui-Sheng Wang,Yuzheng Zhao,Yi Yang,Jin Huang,David E. Hill,Marc Vidal,Charis Eng,Joseph Loscalzo +13 more
TL;DR: A network-based methodology to identify individualized disease modules by mapping patients’ DNA and RNA sequencing profiles to the interactome, enabling prediction of cancer type-specific drug responses and prediction of drug responses is introduced.